<DOC>
	<DOCNO>NCT01854528</DOCNO>
	<brief_summary>The purpose study evaluate safety antiviral activity 3 direct-acting antiviral agent ( DAAs ; ABT-450/ritonavir/ABT-267 [ ABT-450/r/ABT-267 ; ABT-267 also know ombitasvir ] ABT-333 [ also know dasabuvir ] ) plus ribavirin ( RBV ) compare telaprevir ( TPV ) pegylated interferon/ribavirin ( pegIFN/RBV ) patient chronic hepatitis C virus genotype 1 ( HCV GT1 ) infection without cirrhosis previously treat pegylated interferon/ribavirin ( pegIFN/RBV ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Three Experimental Drugs Compared With Telaprevir ( Licensed Product ) Treatment Chronic Hepatitis C Infection Treatment-experienced Adults</brief_title>
	<detailed_description>A randomized , open-label , parallel-arm , multicenter study evaluate safety antiviral activity 3-DAA regimen ( ABT-450/ritonavir/ABT-267 [ ABT-450/r/ABT-267 ] ABT-333 ) plus ribavirin ( 3-DAA/RBV ) compare combination telaprevir ( TPV ) RBV pegIFN ( TPV/RBV ) noncirrhotic participant chronic hepatitis C virus genotype 1 ( HCV GT1 ) infection previously treat pegylated interferon/ribavirin ( pegIFN/RBV ) . Participants randomize 2:1 ratio receive 3-DAA/RBV ( ABT-450/r/ABT-267 ABT-333 plus RBV 12 week ) TPV/RBV ( TPV co-administered pegIFN RBV 12 week , follow follow pegIFN RBV either 12 36 week , per local prescribe information ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Chronic hepatitis C infection ( positive antiHCV antibody HCV RNA least 6 month screen time screening ; positive antiHCV antibody HCV RNA time screen liver biopsy consistent chronic HCV infection ) Screening laboratory result indicate HCV genotype 1 infection ( HCV GT1 ) Participant must documentation adherence prior pegIFN/RBV combination therapy meet one protocol definition treatment failure : null responder , partial responder , relapser No evidence liver cirrhosis Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody Positive screen drug alcohol Significant sensitivity drug Use contraindicate medication within 2 week dose Abnormal laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Partial responder</keyword>
	<keyword>Interferon free</keyword>
	<keyword>Treatment-experienced</keyword>
	<keyword>Relapser</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Null responder</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>dasabuvir</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Viekira PAK</keyword>
	<keyword>Chronic hepatitis C</keyword>
</DOC>